Ischemic cardiomyopathy and myocardial infarction (MI) are typified by the irreversible loss of cardiac muscle (cardiomyocytes) and vasculature (composed of endothelial cells and smooth muscle cells), which are essential for maintaining cardiac integrity and function. The recent identification of adult and embryonic stem cells has triggered attempts to directly repopulate these tissues by stem cell transplantation as a novel therapeutic option. Reports describing provocative and hopeful examples of myocardial regeneration with adult stem/progenitor cells have furthered enthusiasm for the use of these cells, however many unanswered questions remain regarding their therapeutic potential and, more specifically the mechanisms responsible for the observed therapeutic effects. First, although various adult BM-derived stem cell populations have been employed in an attempt to regenerate myocardium, currently no human adult stem cells have been convincingly shown to have the capacity to induce both a therapeutic level of neovascularization and cardiomyogenesis, two of the key components for successful myocardial tissue regeneration. Second, there has been a degree of discrepancy between the therapeutic effect demonstrated in vivo and the magnitude of adult stem/progenitor (trans)differentiation into specific cell lineages. Third, although chronic post-MI heart failure is one of the most clinically relevant candidates for stem cell therapy, this therapeutic approach has been virtually uninvestigated. We recently identified a novel SC population within adult human and rat bone marrow (BM), which can be isolated at a single cell level and can be expanded for more than 120 population doublings (PDs)(> 9 consecutive months). These stem cells demonstrated a potential for differentiation into cells of all three germ layers; mesoderm(endothelium, smooth muscle cells and cardiomyocytes), endoderm and neuroectoderm. We refer to these cells as BM-derived multipotent stem cells (BMSCs). Accordingly we hypothesize that transplantation of human BMSC (hBMSC) may improve cardiac function in animal models of ischemic heart diseases and the mechanisms may encompass not only cellular differentiation but also delivery of multiple humoral factors.
In Specific Aim 1, we will explore the therapeutic impact of myocardial hBMSC transplantation in acute and chronic models of ischemic heart failure, which are the two most clinically relevant candidates for SC therapy.
In Specific Aim 2, using cardiac samples obtained from the above experiments, we will explore local cellular and paracrine mechanisms which can mediate the therapeutic effect of hBMSC transplantation. More specifically, this will encompass cellular differentiation from hBMSC, fusion between hBMSC and host myocardium, expression of muitiple paracrine factors, and proliferative and pro-survival effects on host myocardium.
In SpecificAim 3, we will investigate the systemic effect of hBMSC transplantation. Specifically,we will examine whether myocardial hBMSC transplantation can induce mobilization and recruitment of host circulating stem/progenitor cells and furthermore, explore the possibility of augmenting this natural process with the use of cytokines, thereby enhancing therapeutic efficacy. We anticipate that the results of the experiments outlined in this Proposal will yield new insight into the application of novel BM-derived human stem cells for regeneration of damaged myocardium, and potentially suggest novel therapeutic strategies for acute and chronic forms of heart failure.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL079137-02
Application #
6994435
Study Section
Cardiac Contractility, Hypertrophy, and Failure Study Section (CCHF)
Program Officer
Buxton, Denis B
Project Start
2004-12-15
Project End
2008-11-30
Budget Start
2005-12-01
Budget End
2006-11-30
Support Year
2
Fiscal Year
2006
Total Cost
$402,806
Indirect Cost
Name
St. Elizabeth's Medical Center of Boston
Department
Type
DUNS #
073797292
City
Boston
State
MA
Country
United States
Zip Code
01235
Kim, Sung-Whan; Kim, Hyongbum; Cho, Hyun-Jai et al. (2010) Human peripheral blood-derived CD31+ cells have robust angiogenic and vasculogenic properties and are effective for treating ischemic vascular disease. J Am Coll Cardiol 56:593-607
Kim, Hyongbum; Cho, Hyun-Jai; Kim, Sung-Whan et al. (2010) CD31+ cells represent highly angiogenic and vasculogenic cells in bone marrow: novel role of nonendothelial CD31+ cells in neovascularization and their therapeutic effects on ischemic vascular disease. Circ Res 107:602-14
Kim, Hyongbum; Kim, Sung-Whan; Nam, Douglas et al. (2009) Cell therapy with bone marrow cells for myocardial regeneration. Antioxid Redox Signal 11:1897-911
Kim, Hyongbum; Park, Jong-seon; Choi, Yong Jin et al. (2009) Bone marrow mononuclear cells have neurovascular tropism and improve diabetic neuropathy. Stem Cells 27:1686-96
Jeong, Jin-Ok; Kim, Mee-Ohk; Kim, Hyongbum et al. (2009) Dual angiogenic and neurotrophic effects of bone marrow-derived endothelial progenitor cells on diabetic neuropathy. Circulation 119:699-708
Tressel, Sarah L; Kim, Hyongbum; Ni, Chih-Wen et al. (2008) Angiopoietin-2 stimulates blood flow recovery after femoral artery occlusion by inducing inflammation and arteriogenesis. Arterioscler Thromb Vasc Biol 28:1989-95
Cho, Hyun-Jai; Lee, Namho; Lee, Ji Yoon et al. (2007) Role of host tissues for sustained humoral effects after endothelial progenitor cell transplantation into the ischemic heart. J Exp Med 204:3257-69
Cho, Hyun-Jai; Lee, Juyong; Wecker, Andrea et al. (2006) Bone marrow-derived stem cell therapy in ischemic heart disease. Regen Med 1:337-45
Cho, Hyun-Jai; Yoon, Young-sup (2006) Synergism of hematopoietic cytokines for infarct repair. Circ Res 98:990-2